Advicenne Withdraws U.S. NDA for ADV7103 Amid FDA Review Challenges…

Event summary

Advicenne withdraws its New Drug Application (NDA) for ADV7103 in the U.S. due to additional Chemistry, Manufacturing and Controls (CMC) requirements identified during FDA review.
ADV7103 (Sibnayal®) is already approved in the EU, UK, Saudi Arabia, and UAE, and marketed in over 25 European countries.
The company will host a webinar for shareholders on September 1, 2026, to discuss the decision.

The big picture

Advicenne's withdrawal of the ADV7103 NDA highlights the challenges biotech companies face in navigating FDA regulatory requirements. The decision underscores the importance of robust CMC data in securing approvals, particularly for treatments targeting rare diseases. This setback could delay Advicenne's U.S. market entry, where it competes with established players and seeks to capture a niche in rare kidney disease treatments.

What we're watching

Regulatory Strategy: How Advicenne will address the FDA's CMC requirements and whether it will resubmit the NDA in the future.
Market Expansion: The impact of this setback on Advicenne's ability to expand into the lucrative U.S. market, where it currently lacks approval.
Investor Confidence: The reaction of investors to this withdrawal, particularly given the company's reliance on Sibnayal® for growth.